Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoLithium NP03 proof-of-concept study in moderate-to-severe Alzheimer's disease
2021-001273-23Phase 2Completed
- Sponsor
- Medesis Pharma
- Start
- Jun 2021
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing NanoLithium NP03 with Placebo (2 arms). Primary endpoint: Change in Neuropsychiatric Inventory score. Started Jun 2021; status: completed.
02
Drugs
NanoLithium NP03
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-001273-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001273-23.